Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : T22
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Triastek’s 3D Printed Product T22 Receives FDA Clearance for IND Application
Details : T22 is a world's first 3D printed gastric retention product. It is being evaluated in preclinical studies for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Brand Name : T22
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
January 31, 2024
Lead Product(s) : T22
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : T21
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : T21 is Triastek’s third 3D printed oral colon-targeted delivery drug product, and is an oral, colon-targeted delivery drug for moderate to severe ulcerative colitis (UC).
Brand Name : T21
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
July 20, 2023
Lead Product(s) : T21
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : T21
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Triastek Receives FDA IND Clearance for 3D Printed Medicine
Details : T21 is a novel potential treatment capable of colon-targeted drug delivery. With a unique 3D dosage form design, T21 can reach the targeted colon segment of the GI tract.
Brand Name : T21
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
November 21, 2022
Lead Product(s) : T21
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : T19
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Matrix Partners China
Deal Size : $50.0 million
Deal Type : Series B Financing
Details : The novel design made possible by 3D printing allows T19 to function as a chronotherapeutic drug delivery system, targeting the circadian nature of RA symptoms.
Brand Name : T19
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 14, 2021
Lead Product(s) : T19
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Matrix Partners China
Deal Size : $50.0 million
Deal Type : Series B Financing
Lead Product(s) : T19
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA
Details : United States Food and Drug Administration (FDA) has approved Triastek's Investigational New Drug (IND) 505(b)(2) application for its first 3D printed drug product – T19, indicated for the treatment of rheumatoid arthritis (RA).
Brand Name : T19
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
February 09, 2021
Lead Product(s) : T19
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?